2024 Fall
MCELLBI 153 001 - LEC 001
Molecular Medicine
Andrew Dillin, Sarah A Stanley
Class #:25178
Units: 4
Instruction Mode:
In-Person Instruction
Offered through
Molecular and Cell Biology
Current Enrollment
Total Open Seats:
-9
Enrolled: 215
Waitlisted: 0
Capacity: 206
Waitlist Max: 30
No Reserved Seats
Hours & Workload
3 hours of instructor presentation of course materials per week, 8 hours of outside work hours per week, and 1 hours of the exchange of opinions or questions on course material per week.
Final Exam
MON, DECEMBER 16TH
08:00 am - 11:00 am
Evans 60
Physics Building 2
Joan and Sanford I. Weill 101
Other classes by Andrew Dillin
Other classes by Sarah A Stanley
Course Catalog Description
The overarching goal of MCB153 is to convey to students the scientific and regulatory process by which therapeutic drugs are developed and created. After completing this course, students will have a firm understanding on the mechanism of action of several therapies used to fight disease. The course will cover areas such as the discovery and refinement of antibiotics, anti-virals, cancer therapies and CRISPR-based therapies. Furthermore, MCB153 will delve into disease areas not covered in other courses, such as autoimmune diseases, cardiovascular diseases and neurological diseases. Lastly, MCB153 will implement a “case study” for each topic displaying real world challenges and solutions to treating complex diseases.
Class Notes
Most seats are reserved for declared MCB IMM majors until July 25, 2024. Unclaimed seats will be released to the waitlisted students after the date.
Rules & Requirements
Repeat Rules
Course is not repeatable for credit.
Reserved Seats
Current Enrollment
No Reserved Seats
Textbooks & Materials
See class syllabus or https://calstudentstore.berkeley.edu/textbooks for the most current information.
Guide to Open, Free, & Affordable Course Materials